August 2012 – The CenterWatch Monthly : Print
Investigator-initiated trials see dramatic drop
Over the past five years, biopharmaceutical companies have invested significant resources building processes to track and manage investigator initiated trial (IIT) programs, in response to increased regulatory pressures. Yet the number of Investigational New Drug (IND) applications filed by independent investigators has declined, as grant spending for IIT programs has slowed at many companies.
Sponsors seeking preferred relationships with best sites
Productivity in the clinical trials industry has been trending negatively, as a reflection of more complex protocols and poor enrollment statistics of study sites. In the hope of shortening recruitment timelines and deflating study budgets, sponsors have been engaging larger numbers of sites to each enroll fewer patients in an attempt to more quickly hit their targets.
Eye On: Allergan
Allergan is a $4.8 billion, multi-specialty healthcare company identifying itself as “global in reach, specialized in focus.” It employs about 10,000 worldwide and maintains a presence in more than 100 countries. By collaborating with medical specialists who provide their perspectives on unmet patient needs, Allergan aims to discover, develop and market innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products “that enable people to live life to its greatest potential.”...
- The science of site selection
- The case for life sciences analytics
- Regulatory Update
- Month in Review
- CRO Industry Update
- Study Lead Opportunities